Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - formoterol fumarate - inhalation powder, hard capsule - 12 microgram(s) - selective beta-2-adrenoreceptor agonists; formoterol

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.copdsymptomatic treatment of patients with severe copd (fev1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva pharma b.v. is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva pharma b.v. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. 

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

teva pharma b.v.  - budesonide, formoterol fumarate dihydrate - asthma; pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - budesonide/formoterol teva pharma b.v. is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva pharma b.v. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.copdsymptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev1) 

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - formoterol fumarate dihydrate -

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk - formoterol fumarate dihydrate - inhalation powder - 12microgram/1dose

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - formoterol fumatrate dihydrate - powder for inhalation - 6 microgram(s) - selective beta-2-adrenoreceptor agonists; formoterol

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

cipla usa inc. - arformoterol tartrate (unii: 5p8vj2i235) (arformoterol - unii:f91h02ebwt) - arformoterol tartrate inhalation solution is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. arformoterol tartrate inhalation solution is for use by nebulization only. arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see warnings and precautions (5.2) ]. arformoterol tartrate inhalation solution is not indicated to treat asthma. the safety and effectiveness of arformoterol tartrate inhalation solution in asthma have not been established. arformoterol tartrate inhalation solution is contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any other components of this product. use of a laba, including arformoterol tartrate inhalation solution, without an inhaled cortisteroid is contraindicated in patients with asthma [s

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - arformoterol tartrate (unii: 5p8vj2i235) (arformoterol - unii:f91h02ebwt) - arformoterol tartrate inhalation solution is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. arformoterol tartrate inhalation solution is for use by nebulization only. arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see warnings and precautions (5.2) ]. arformoterol tartrate inhalation solution is not indicated to treat asthma. the safety and effectiveness of arformoterol tartrate inhalation solution in asthma have not been established. arformoterol tartrate inhalation solution is contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any other components of this product. use of a laba, including arformoterol tartrate inhalation solution, without an inhaled cortisteroid is contraindicated in patients with asthma [s

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

slate run pharmaceuticals - arformoterol tartrate (unii: 5p8vj2i235) (arformoterol - unii:f91h02ebwt) - arformoterol tartrate inhalation solution is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. arformoterol tartrate inhalation solution is for use by nebulization only. arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see warnings and precautions(5.2) ]. arformoterol tartrate inhalation solution is not indicated to treat asthma. the safety and effectiveness of arformoterol tartrate inhalation solution in asthma have not been established. arformoterol tartrate inhalation solution is contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any other components of this product. use of a laba, including arformoterol tartrate inhalation solution, without an inhaled cortisteroid is contraindicated in patients with asthma [se